Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine …
WEBAug 16, 2024 · In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives.
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
WEBSep 14, 2022 · First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older; Influenza causes 140,000 to 710,000 hospitalizations and 12,000 to …
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for …
WEBDec 9, 2022 · Pfizer and BioNTech previously announced the start of a Phase 1 trial to examine the safety, tolerability, and immunogenicity of their combined influenza and COVID-19 candidate vaccine among healthy adults.
Big mRNA players focus on flu vaccines | Nature Biotechnology
WEBDec 7, 2022 · Pfizer and BioNTech’s mRNA vaccine for influenza and COVID-19 began phase 1 trials in November, joining the growing number of jabs aiming to capitalize on mRNA technology.
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine …
WEBAug 16, 2024 · In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives.
Pfizer, BioNTech's mRNA flu vaccine starts phase 3 testing
WEB4 days ago · The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than...
Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 …
WEBAn investigational messenger RNA (mRNA)–based vaccine designed to protect against both influenza and COVID-19 induced virus-specific immune responses in people who received it, manufacturers Pfizer and BioNTech announced in a press release.
Pfizer and BioNTech Announce Positive Topline Data for mRNA …
WEBOct 26, 2023 · Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19. October 26, 2023. Share. X. Join Pfizer Investor Insights. Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders.
Developing a Potential mRNA Influenza Vaccine
WEBSep 23, 2022 · Since 2018, Pfizer has been working to develop a potential mRNA influenza vaccine, after entering into a collaboration agreement with BioNTech. Pfizer is committed to continuing to advance mRNA technology to unlock its full potential for the benefit of patients around the world.
COVID, flu combo jab from Pfizer/BioNTech heads for phase 3
WEBOct 26, 2023 · A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a pivotal phase 3...